within Pharmacolibrary.Drugs.ATC.J;

model J05AX26
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.87,
    Cl             = 0.00025,
    adminDuration  = 600,
    adminMass      = 400 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.139,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.013500000000000002,
    Tlag           = 10.200000000000001,            
    Vdp             = 0.061,
    k12             = 18.7,
    k21             = 18.7
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J05AX26</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Amenamevir is an orally active helicase-primase inhibitor used for the treatment of herpes zoster (shingles) in adults. It is approved and marketed in Japan for this indication. Amenamevir inhibits the helicase-primase complex essential for herpesvirus DNA replication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult Japanese volunteers receiving single oral doses of amenamevir.</p><h4>References</h4><ol><li><p>Tsuruoka, S, et al., &amp; Hashimoto, N (2020). Pharmacokinetics and Dialyzability of a Single Oral Dose of Amenamevir, an Anti-Herpes Drug, in Hemodialysis Patients. <i>Advances in therapy</i> 37(7) 3234–3245. DOI:<a href=&quot;https://doi.org/10.1007/s12325-020-01375-1&quot;>10.1007/s12325-020-01375-1</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32440976/&quot;>https://pubmed.ncbi.nlm.nih.gov/32440976</a></p></li><li><p>Kusawake, T, et al., &amp; Katashima, M (2017). Pharmacokinetics and Safety of Amenamevir in Healthy Subjects: Analysis of Four Randomized Phase 1 Studies. <i>Advances in therapy</i> 34(12) 2625–2637. DOI:<a href=&quot;https://doi.org/10.1007/s12325-017-0642-4&quot;>10.1007/s12325-017-0642-4</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29134426/&quot;>https://pubmed.ncbi.nlm.nih.gov/29134426</a></p></li><li><p>Tsuruoka, S, et al., &amp; Hashimoto, N (2020). Correction to: Pharmacokinetics and Dialyzability of a Single Oral Dose of Amenamevir, an Anti-Herpes Drug, in Hemodialysis Patients. <i>Advances in therapy</i> 37(11) 4758–4764. DOI:<a href=&quot;https://doi.org/10.1007/s12325-020-01489-6&quot;>10.1007/s12325-020-01489-6</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32930967/&quot;>https://pubmed.ncbi.nlm.nih.gov/32930967</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J05AX26;
